$ACER Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Acer Therapeutics Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Acer Therapeutics Inc.. Get notifications about new insider transactions in Acer Therapeutics Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 05 2021 | ACER | Acer Therapeutics ... | Davis Jefferson E | Chief Business Offi ... | Option Exercise | A | 3.89 | 100,000 | 389,000 | 100,000 | |
| Feb 05 2021 | ACER | Acer Therapeutics ... | Davis Jefferson E | Chief Business Offi ... | Option Exercise | A | 3.89 | 100,000 | 389,000 | 100,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | Seibt Matthew | Chief Commercial Of ... | Option Exercise | A | 3.85 | 20,000 | 77,000 | 20,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | Schelling Chris | President & CEO | Option Exercise | A | 3.85 | 40,000 | 154,000 | 40,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | PALMIN HARRY S | Chief Opp. and Fina ... | Option Exercise | A | 3.85 | 60,000 | 231,000 | 60,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | Klopp John Michael | Chief Technical Off ... | Option Exercise | A | 3.85 | 20,000 | 77,000 | 20,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | Joseph Donald | Chief Legal Officer ... | Option Exercise | A | 3.85 | 60,000 | 231,000 | 60,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | GRIFFIN MICHELLE RENEE | Director | Option Exercise | A | 3.85 | 15,000 | 57,750 | 15,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | DUNN JOHN MICHAEL | Director | Option Exercise | A | 3.85 | 15,000 | 57,750 | 15,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 3.85 | 15,000 | 57,750 | 15,000 | |
| Jan 20 2021 | ACER | Acer Therapeutics ... | Amello Jason | Director | Option Exercise | A | 3.85 | 15,000 | 57,750 | 15,000 | |
| Jul 28 2020 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Buy | P | 3.50 | 45,000 | 157,500 | 63,905 | 18.9 K to 63.9 K (+238.03 %) |
| Jul 28 2020 | ACER | Acer Therapeutics ... | DUNN JOHN MICHAEL | Director | Buy | P | 3.50 | 21,428 | 74,998 | 27,380 | 6 K to 27.4 K (+360.01 %) |
| Jul 28 2020 | ACER | Acer Therapeutics ... | Joseph Donald | Chief Legal Officer ... | Buy | P | 3.50 | 14,285 | 49,998 | 14,285 | 0 to 14.3 K |
| Jul 28 2020 | ACER | Acer Therapeutics ... | Schelling Chris | President & CEO | Buy | P | 3.50 | 142,857 | 500,000 | 1,892,857 | 1.8 M to 1.9 M (+8.16 %) |
| Mar 04 2020 | ACER | Acer Therapeutics ... | Andrews William T. | Chief Medical Offic ... | Payment of Exercise | F | 3.28 | 3,142 | 10,306 | 5,858 | 9 K to 5.9 K (-34.91 %) |
| Jan 03 2020 | ACER | Acer Therapeutics ... | GRIFFIN MICHELLE RENEE | Director | Option Exercise | A | 3.79 | 9,000 | 34,110 | 9,000 | |
| Jan 03 2020 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 3.79 | 9,000 | 34,110 | 9,000 | |
| Sep 25 2019 | ACER | Acer Therapeutics ... | Klopp John Michael | Chief Technology Of ... | Option Exercise | A | 3.42 | 50,000 | 171,000 | 50,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | PALMIN HARRY S | Chief Opp. and Fina ... | Option Exercise | A | 3.42 | 40,000 | 136,800 | 40,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | Joseph Donald | Chief Legal Officer ... | Option Exercise | A | 3.42 | 40,000 | 136,800 | 40,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | Andrews William T. | Chief Medical Offic ... | Option Exercise | A | 3.42 | 40,000 | 136,800 | 40,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | Seibt Matthew | Chief Commercial Of ... | Option Exercise | A | 3.42 | 50,000 | 171,000 | 50,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | PALMIN HARRY S | Chief Opp. and Fina ... | Option Exercise | A | 3.42 | 40,000 | 136,800 | 40,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | Joseph Donald | Chief Legal Officer ... | Option Exercise | A | 3.42 | 40,000 | 136,800 | 40,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | Andrews William T. | Chief Medical Offic ... | Option Exercise | A | 3.42 | 40,000 | 136,800 | 40,000 | |
| Sep 23 2019 | ACER | Acer Therapeutics ... | Seibt Matthew | Chief Commercial Of ... | Option Exercise | A | 3.42 | 50,000 | 171,000 | 50,000 | |
| Jul 05 2019 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Buy | P | 3.72 | 5,000 | 18,581 | 18,905 | 13.9 K to 18.9 K (+35.96 %) |
| Mar 05 2019 | ACER | Acer Therapeutics ... | Andrews William T. | Chief Medical Offic ... | Grant | A | 0.00 | 9,000 | 0 | 9,000 | 0 to 9 K |
| Feb 05 2019 | ACER | Acer Therapeutics ... | Schelling Chris | President and Chief ... | Option Exercise | A | 24.46 | 72,500 | 1,773,350 | 72,500 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | PALMIN HARRY S | Chief Opp. and Fina ... | Option Exercise | A | 24.46 | 27,000 | 660,420 | 27,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | Joseph Donald | Chief Legal Officer ... | Option Exercise | A | 24.46 | 27,000 | 660,420 | 27,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | GRIFFIN MICHELLE RENEE | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | GRIFFIN MICHELLE RENEE | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | DUNN JOHN MICHAEL | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | DUNN JOHN MICHAEL | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | ASELAGE STEVE | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | Andrews William T. | Chief Medical Offic ... | Option Exercise | A | 24.46 | 27,000 | 660,420 | 27,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | Andrews William T. | Chief Medical Offic ... | Option Exercise | A | 24.46 | 27,000 | 660,420 | 27,000 | |
| Feb 05 2019 | ACER | Acer Therapeutics ... | Amello Jason | Director | Option Exercise | A | 24.46 | 6,000 | 146,760 | 6,000 | |
| Dec 06 2018 | ACER | Acer Therapeutics ... | Jutt-Eghbali Salma | Chief Commercial Of ... | Option Exercise | A | 22.18 | 60,000 | 1,330,800 | 60,000 | |
| Aug 22 2018 | ACER | Acer Therapeutics ... | TVM Life Science Ventures VII ... | Director | Buy | P | 18.00 | 275,000 | 4,950,000 | 1,697,709 | 1.4 M to 1.7 M (+19.33 %) |
| Apr 23 2018 | ACER | Acer Therapeutics ... | Joseph Donald | Chief Legal Officer ... | Option Exercise | A | 18.53 | 60,000 | 1,111,800 | 60,000 | |
| Jan 12 2018 | OPXA | Acer Therapeutics ... | TVM Life Science Ventures VI G ... | Director | Buy | P | 12.00 | 250,000 | 3,000,000 | 1,422,709 | 1.2 M to 1.4 M (+21.32 %) |
| Jan 12 2018 | OPXA | Acer Therapeutics ... | TVM Life Science Ventures VI G ... | Director | Buy | P | 12.00 | 21,271 | 255,252 | 248,756 | 227.5 K to 248.8 K (+9.35 %) |
| Jan 12 2018 | OPXA | Acer Therapeutics ... | TVM Life Science Ventures VI G ... | Director | Buy | P | 12.00 | 62,062 | 744,744 | 725,844 | 663.8 K to 725.8 K (+9.35 %) |
| Dec 18 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Director | Buy | P | 12.00 | 2,000 | 24,000 | 13,905 | 11.9 K to 13.9 K (+16.80 %) |
| Oct 06 2017 | OPXA | Acer Therapeutics ... | Andrews William T. | Chief Medical Offic ... | Option Exercise | A | 15.34 | 100,000 | 1,534,000 | 100,000 | |
| Oct 06 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Option Exercise | A | 15.34 | 6,000 | 92,040 | 6,000 | ||
| Oct 06 2017 | OPXA | Acer Therapeutics ... | GRIFFIN MICHELLE RENEE | Option Exercise | A | 15.34 | 9,000 | 138,060 | 9,000 | ||
| Oct 06 2017 | OPXA | Acer Therapeutics ... | DUNN JOHN MICHAEL | Option Exercise | A | 15.34 | 6,000 | 92,040 | 6,000 | ||
| Oct 06 2017 | OPXA | Acer Therapeutics ... | Amello Jason | Option Exercise | A | 15.34 | 9,000 | 138,060 | 9,000 | ||
| Oct 06 2017 | OPXA | Acer Therapeutics ... | PALMIN HARRY S | Chief Financial Off ... | Option Exercise | A | 15.34 | 67,600 | 1,036,984 | 67,600 | |
| Oct 06 2017 | OPXA | Acer Therapeutics ... | Schelling Chris | President and CEO | Option Exercise | A | 15.34 | 46,000 | 705,640 | 46,000 | |
| Sep 27 2017 | OPXA | Acer Therapeutics ... | TVM Life Science Ventures VI G ... | Director | Buy | J | 0.00 | 1,172,709 | 0 | 1,172,709 | 0 to 1.2 M |
| Sep 27 2017 | OPXA | Acer Therapeutics ... | TVM Life Science Ventures VI G ... | Director | Buy | J | 0.00 | 227,485 | 0 | 227,485 | 0 to 227.5 K |
| Sep 27 2017 | OPXA | Acer Therapeutics ... | TVM Life Science Ventures VI G ... | Director | Buy | J | 0.00 | 663,782 | 0 | 663,782 | 0 to 663.8 K |
| Sep 21 2017 | OPXA | Acer Therapeutics ... | Steiner Robert D | Chief Medical Offic ... | Option Exercise | J | 2.55 | 40,000 | 102,000 | 40,000 | |
| Sep 21 2017 | OPXA | Acer Therapeutics ... | PALMIN HARRY S | Chief Financial Off ... | Buy | J | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Sep 21 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Option Exercise | J | 2.55 | 21,000 | 53,550 | 21,000 | ||
| Sep 21 2017 | OPXA | Acer Therapeutics ... | ASELAGE STEVE | Buy | J | 0.00 | 11,905 | 0 | 11,905 | 0 to 11.9 K | |
| Sep 21 2017 | OPXA | Acer Therapeutics ... | DUNN JOHN MICHAEL | Option Exercise | J | 2.55 | 16,000 | 40,800 | 16,000 | ||
| Sep 21 2017 | OPXA | Acer Therapeutics ... | DUNN JOHN MICHAEL | Buy | J | 0.00 | 5,952 | 0 | 5,952 | 0 to 6 K | |
| Sep 21 2017 | OPXA | Acer Therapeutics ... | Schelling Chris | President and CEO | Buy | J | 0.00 | 1,750,000 | 0 | 1,750,000 | 0 to 1.8 M |
| Nov 22 2016 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Option Exercise | S | 12.00 | 16,000 | 192,000 | 0 | |
| Nov 22 2016 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Sell | S | 0.55 | 7,809 | 4,302 | 12,910 | 20.7 K to 12.9 K (-37.69 %) |
| Nov 22 2016 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Sell | S | 0.55 | 7,105 | 3,908 | 20,719 | 27.8 K to 20.7 K (-25.54 %) |
| Oct 04 2016 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Grant | A | 0.00 | 6,455 | 0 | 29,989 | 23.5 K to 30 K (+27.43 %) |
| Oct 04 2016 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Grant | A | 0.00 | 6,455 | 0 | 25,884 | 19.4 K to 25.9 K (+33.22 %) |
| Oct 04 2016 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 6,455 | 0 | 25,884 | 19.4 K to 25.9 K (+33.22 %) |
| Oct 04 2016 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 6,455 | 0 | 27,824 | 21.4 K to 27.8 K (+30.21 %) |
| Jul 01 2016 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 6,455 | 0 | 19,429 | 13 K to 19.4 K (+49.75 %) |
| Jul 01 2016 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 6,455 | 0 | 21,369 | 14.9 K to 21.4 K (+43.28 %) |
| Jul 01 2016 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Grant | A | 0.00 | 6,455 | 0 | 23,534 | 17.1 K to 23.5 K (+37.79 %) |
| Jul 01 2016 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Grant | A | 0.00 | 6,455 | 0 | 19,429 | 13 K to 19.4 K (+49.75 %) |
| May 18 2016 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Grant | A | 0.00 | 6,455 | 0 | 12,974 | 6.5 K to 13 K (+99.02 %) |
| May 18 2016 | OPXA | Opexa Therapeutics ... | Warma Neil K | President, CEO and ... | Option Exercise | A | 2.13 | 50,000 | 106,500 | 50,000 | |
| May 18 2016 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Grant | A | 0.00 | 6,455 | 0 | 17,079 | 10.6 K to 17.1 K (+60.76 %) |
| May 18 2016 | OPXA | Opexa Therapeutics ... | Rill Donna R | Chief Development O ... | Option Exercise | A | 2.13 | 50,000 | 106,500 | 50,000 | |
| May 18 2016 | OPXA | Opexa Therapeutics ... | Healey Don | Chief Scientific Of ... | Option Exercise | A | 2.13 | 50,000 | 106,500 | 50,000 | |
| May 18 2016 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 6,455 | 0 | 12,974 | 6.5 K to 13 K (+99.02 %) |
| May 18 2016 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 6,455 | 0 | 14,914 | 8.5 K to 14.9 K (+76.31 %) |
| Jan 04 2016 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 1,354 | 0 | 6,520 | 5.2 K to 6.5 K (+26.21 %) |
| Jan 04 2016 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 1,354 | 0 | 8,460 | 7.1 K to 8.5 K (+19.05 %) |
| Jan 04 2016 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Grant | A | 0.00 | 1,354 | 0 | 6,520 | 5.2 K to 6.5 K (+26.21 %) |
| Oct 02 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Grant | A | 0.00 | 1,200 | 0 | 5,166 | 4 K to 5.2 K (+30.26 %) |
| Oct 02 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 1,200 | 0 | 5,166 | 4 K to 5.2 K (+30.26 %) |
| Oct 02 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 1,200 | 0 | 7,106 | 5.9 K to 7.1 K (+20.32 %) |
| Jul 01 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 8,427 | 0 | 47,245 | 38.8 K to 47.2 K (+21.71 %) |
| Jul 01 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Grant | A | 0.00 | 8,427 | 0 | 31,729 | 23.3 K to 31.7 K (+36.16 %) |
| Jul 01 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 8,427 | 0 | 31,729 | 23.3 K to 31.7 K (+36.16 %) |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Warma Neil K | President and CEO | Option Exercise | M | 0.00 | 37,247 | 0 | 37,247 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Warma Neil K | President and CEO | Option Exercise | M | 0.55 | 37,247 | 20,486 | 0 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Warma Neil K | President and CEO | Buy | M | 0.00 | 37,247 | 0 | 144,881 | 107.6 K to 144.9 K (+34.61 %) |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | M | 0.00 | 518,707 | 0 | 518,707 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | M | 0.55 | 518,707 | 285,289 | 0 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | M | 0.00 | 44,087 | 0 | 44,087 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | M | 0.55 | 44,087 | 24,248 | 0 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Buy | M | 0.00 | 518,707 | 0 | 1,037,414 | 518.7 K to 1 M (+100.00 %) |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Buy | M | 0.00 | 44,087 | 0 | 85,000 | 40.9 K to 85 K (+107.76 %) |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Option Exercise | M | 0.00 | 8,242 | 0 | 8,242 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Option Exercise | M | 0.55 | 8,242 | 4,533 | 0 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Buy | M | 0.00 | 8,242 | 0 | 23,302 | 15.1 K to 23.3 K (+54.73 %) |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Radhakrishnan Karthik | Chief Financial Off ... | Option Exercise | M | 0.00 | 50,000 | 0 | 50,000 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Radhakrishnan Karthik | Chief Financial Off ... | Option Exercise | M | 0.55 | 50,000 | 27,500 | 0 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Radhakrishnan Karthik | Chief Financial Off ... | Buy | M | 0.00 | 50,000 | 0 | 124,659 | 74.7 K to 124.7 K (+66.97 %) |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Option Exercise | M | 0.00 | 8,242 | 0 | 8,242 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Option Exercise | M | 0.55 | 8,242 | 4,533 | 0 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Buy | M | 0.00 | 8,242 | 0 | 23,302 | 15.1 K to 23.3 K (+54.73 %) |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Option Exercise | M | 0.00 | 16,000 | 0 | 16,000 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Option Exercise | M | 0.55 | 16,000 | 8,800 | 0 | |
| Apr 09 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Buy | M | 0.00 | 16,000 | 0 | 38,818 | 22.8 K to 38.8 K (+70.12 %) |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Option Exercise | A | 0.53 | 23,804 | 12,616 | 23,804 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Option Exercise | A | 0.53 | 71,410 | 37,847 | 71,410 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Grant | A | 0.00 | 6,818 | 0 | 15,060 | 8.2 K to 15.1 K (+82.72 %) |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | A | 0.53 | 35,706 | 18,924 | 35,706 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | A | 0.53 | 23,804 | 12,616 | 23,804 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | A | 0.53 | 71,410 | 37,847 | 71,410 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Hartung Hans-Peter | Director | Option Exercise | A | 0.53 | 23,804 | 12,616 | 23,804 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Hartung Hans-Peter | Director | Option Exercise | A | 0.53 | 71,410 | 37,847 | 71,410 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Option Exercise | A | 0.53 | 23,804 | 12,616 | 23,804 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Option Exercise | A | 0.53 | 71,410 | 37,847 | 71,410 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 6,818 | 0 | 15,060 | 8.2 K to 15.1 K (+82.72 %) |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Option Exercise | A | 0.53 | 23,804 | 12,616 | 23,804 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Option Exercise | A | 0.53 | 71,410 | 37,847 | 71,410 | |
| Apr 01 2015 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 6,818 | 0 | 22,818 | 16 K to 22.8 K (+42.61 %) |
| Mar 04 2015 | OPXA | Opexa Therapeutics ... | Radhakrishnan Karthik | Chief Financial Off ... | Option Exercise | A | 0.82 | 50,000 | 41,000 | 50,000 | |
| Mar 04 2015 | OPXA | Opexa Therapeutics ... | Warma Neil K | President & CEO | Option Exercise | A | 0.82 | 120,000 | 98,400 | 120,000 | |
| Mar 04 2015 | OPXA | Opexa Therapeutics ... | Rill Donna R | Chief Development O ... | Option Exercise | A | 0.82 | 50,000 | 41,000 | 50,000 | |
| Sep 18 2014 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Buy | P | 1.15 | 10,000 | 11,500 | 16,000 | 6 K to 16 K (+166.67 %) |
| Sep 17 2014 | OPXA | Opexa Therapeutics ... | Warma Neil K | President & CEO | Buy | P | 1.11 | 10,000 | 11,100 | 107,634 | 97.6 K to 107.6 K (+10.24 %) |
| Mar 21 2014 | OPXA | Opexa Therapeutics ... | Hartung Hans-Peter | Director | Option Exercise | A | 2.00 | 6,450 | 12,900 | 6,450 | |
| Mar 21 2014 | OPXA | Opexa Therapeutics ... | Hartung Hans-Peter | Director | Option Exercise | A | 2.00 | 4,300 | 8,600 | 4,300 | |
| Mar 21 2014 | OPXA | Opexa Therapeutics ... | Hartung Hans-Peter | Director | Option Exercise | A | 2.00 | 12,900 | 25,800 | 12,900 | |
| Mar 21 2014 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Option Exercise | A | 2.00 | 4,300 | 8,600 | 4,300 | |
| Mar 21 2014 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Option Exercise | A | 2.00 | 12,900 | 25,800 | 12,900 | |
| Mar 21 2014 | OPXA | Opexa Therapeutics ... | BARABE TIMOTHY C | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Option Exercise | A | 1.82 | 5,896 | 10,731 | 5,896 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Option Exercise | A | 1.82 | 17,686 | 32,189 | 17,686 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Maderis Gail J | Director | Grant | A | 0.00 | 8,242 | 0 | 8,242 | 0 to 8.2 K |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | A | 1.82 | 8,844 | 16,096 | 8,844 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | A | 1.82 | 5,896 | 10,731 | 5,896 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Seaman Scott B | Director | Option Exercise | A | 1.82 | 17,686 | 32,189 | 17,686 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Rill Donna R | Chief Development O ... | Option Exercise | A | 1.82 | 64,625 | 117,618 | 64,625 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Rill Donna R | Chief Development O ... | Grant | A | 0.00 | 12,363 | 0 | 32,765 | 20.4 K to 32.8 K (+60.60 %) |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Warma Neil K | President & CEO | Option Exercise | A | 1.82 | 316,250 | 575,575 | 316,250 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Warma Neil K | President & CEO | Grant | A | 0.00 | 51,748 | 0 | 97,634 | 45.9 K to 97.6 K (+112.78 %) |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Option Exercise | A | 1.82 | 5,896 | 10,731 | 5,896 | |
| Mar 04 2014 | OPXA | Opexa Therapeutics ... | Richman Michael | Director | Option Exercise | A | 1.82 | 17,686 | 32,189 | 17,686 |